Standard Medicine principal investigators will receive nearly $15 million over a four-year term from the National Institutes of Health (NIH) to study long COVID. Stanford is but one of 30 research teams involved with the imminent, nationwide, NIH-sponsored RECOVER (Researching COVID to Enhance Recovery) study. Established to identify risk factors involved with long COVID, as well as to help develop approaches to prevent and treat the condition, the study also seeks to better understand why some people experience the condition while others do not. The Stanford Medicine trial site will enroll 900 COVID-19 survivors, including those complaining of ongoing symptoms that implicate long COVID. The participants are monitored for four years.